Clinical trials: Post-COVID19 Condition
Post COVID-19 Condition (PCC)
Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting
Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up.
- Trial name
- EB-PCC-01 (NCT06113679)
- Testing
- RDX-19
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- EmitBio Inc.
SARS-CoV-2 Infection
Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 (COVID-19) in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.
Double-blind, parallel, randomized, placebo-controlled clinical study. Subjects with confirmed SARS-CoV-2 infection by PCR or antigen rapid test, asymptomatic or with mild COVID-19 symptoms will be included.
- Trial name
- CPC COVID (NCT04757818)
- Testing
- 0.07% cetylpyridinium chloride (CPC) in mouthwash, Distilled water with the same colorant as the experimental product
- Where
- 19 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Dentaid SL
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
COVID-19
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
This is a randomized, double-blind, active-controlled Phase Ⅲ clinical trial, as well as an immuno-bridging clinical trial by parallel testing previous serum after primary immunization of COVID-19 vaccine (Vero cell), inactivated…
- Trial name
- NCT05381350
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Where
- China
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
An Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or K032-120
This observational clinical study aims to evaluate the presence of symptoms of COVID-19 infection in patients who participated in K031-120 or K032-120 ("long hauler").
- Trial name
- NCT04814914
- Testing
- KB109 + Self Supportive Care, Self Supportive Care (SSC) Alone
- Where
- 2 sites in United States
- Volunteers
- 333 people
- Sponsor
- Kaleido Biosciences
COVID-19 Vaccination
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
This study is to identify any problems and questions with respect to the safety of Comirnaty Injection (Bretovameran) during the post-marketing period.
- Trial name
- NCT06613984
- Testing
- Bretovameran
- Where
- South Korea
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Pfizer
Long COVID
Study of LAU-7b for the Treatment of Long COVID in Adults
ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.
- Trial name
- ESSOR (NCT05999435)
- Testing
- LAU-7b for 3 cycles
- Where
- 5 sites in Canada
- Volunteers
- 272 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Respiratory Viral Infection, Respiratory Tract Diseases
PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)
This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.
- Conditions
- Respiratory Viral Infection, Respiratory Tract Diseases, COVID-19 Respiratory Infection
- Trial name
- PREVENT (NCT04842331)
- Testing
- RESP301 (a nitric oxide generating solution), Standard of Care (SOC)
- Where
- United Kingdom
- Sponsor
- Thirty Respiratory Limited
COVID-19
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom.
- Trial name
- NCT07090486
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 14,000 people
- Sponsor
- Pfizer
Fibroses, Pulmonary
Study of Longidaze in the Prevention & Treatment of Pulmonary Fibrosis, Interstitial Lung Diseases Caused by COVID-19
A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.
- Trial name
- NCT04645368
- Testing
- bovhyaluronidase azoxymer
- Where
- 15 sites in Russia
- Volunteers
- 160 people
- Sponsor
- NPO Petrovax
SARS-CoV-2 Infection
Halodine Nasal Antiseptic in Patients With COVID-19
Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent that has a long history of safe and effective use.
- Trial name
- NCT04517188
- Testing
- Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
- Volunteers
- 40 people
- Sponsor
- Halodine LLC
SARS-CoV-2 Acute Respiratory Disease
Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population
The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210 million cases worldwide as of September 1, 2021.
- Trial name
- COVCAL (NCT05135585)
- Testing
- Blood sample collection, Questionnaires
- Where
- 3 sites in New Caledonia
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
SARS-CoV-2 Infection, Lung Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind…
- Trial name
- NCT05516550
- Testing
- Treamid, Treamid twice a day, Treamid once a day
- Volunteers
- 412 people
- Sponsor
- PHARMENTERPRISES LLC
Post-Acute COVID-19 Syndrome, Cognitive Impairment
Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).
The study, identified as VIX001-PACS-01, is a Phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute…
- Conditions
- Post-Acute COVID-19 Syndrome, Cognitive Impairment, Neurological Complication
- Trial name
- NCT05947617
- Testing
- VIX001
- Volunteers
- 9 people
- Sponsor
- Neobiosis, LLC
Severe Acute Respiratory Syndrome, Coronavirus
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
- Conditions
- Severe Acute Respiratory Syndrome, Coronavirus, SARS-CoV-2, COVID-19
- Trial name
- NCT04449276
- Testing
- CVnCoV Vaccine
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine
This is an open-label, single-arm clinical trial designed to evaluate the immunogenicity and safety of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co.
- Trial name
- NCT05285384
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 43 people
- Sponsor
- Cinnagen
Long COVID
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.
- Trial name
- IMPACT-LC (NCT06974084)
- Testing
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- HealthBio, Inc.
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
covid19
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
The primary objective of this study is to evaluate the efficacy of the drug nitazoxanide 600 mg, administered three times a day, in relation to placebo in preventing the development of COVID-19 in subjects from vulnerable…
- Trial name
- NCT04435314
- Testing
- Nitazoxanide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Managed Access Programs for INC424, Ruxolitinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness
- Trial name
- NCT04745637
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals